Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially when milestone payments are involved, explain experts ta Venable LLP.
- Innovative Strategies In Early Commercialization: A Leader's Perspective
- Promoting A Newly Approved Indication Against Established Competitors
- The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials
- Navigating The GLP-1 Litigation Landscape
- The Convergence Of Consumer Wellness And Healthcare
- Planning For Perseverance
- Building Uniquity Bio: Teams, Capital, And Strategy
- A Better Way For BD And Commercial Teams To Evaluate Strategic Assets
COMPANIES TO WATCH
-
Companies To Watch: ImunonImunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
![Tim Lu_Senti Bio]( "Companies To Watch: Senti Bio")
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
WHERE ARE THEY NOW
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus PharmaceuticalsTarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 05.23.25 -- Planning For Perseverance
- 05.22.25 -- Innovations In Multispecific Antibody Development: Strategies & Platforms
- 05.21.25 -- A Better Way For BD And Commercial Teams To Evaluate Strategic Assets
- 05.20.25 -- Innovative Solutions For Complex Clinical Trials
- 05.19.25 -- Key Insights On Building Teams, Securing Capital, And Operating With Efficiency
SPOTLIGHT
Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.
